Measurable Residual Disease in Cancer: 2nd Edition
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: 25 December 2025 | Viewed by 96
Special Issue Editors
Interests: hematological neoplasm
Interests: chronic lymphocytic leukemia; multiple myeloma; light chain amyloidosis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This is the 2nd edition of the previous Special Issue: Measurable Residual Disease in Cancer.
Measurable residual disease (MRD; previously termed minimal residual disease) refers to the presence of cancer cells below the threshold of detection when using conventional methods of assessing response to treatment. Depending on the type of tumor, MRD can be evaluated using a variety of techniques, most of which are in constant evolution, and new techniques are still being developed. Importantly, with the significant advances in therapeutic approaches in recent decades to obtain deep responses, MRD has become an important post-therapy prognostic indicator in many types of cancer. Moreover, in some tumors, MRD assessment has become a key factor in risk stratification and treatment planning in clinical practice. MRD is also a widely used endpoint in clinical trials assessing novel drugs and treatment strategies.
It should be noted, however, that in many neoplasms, the methods for assessing MRD have not yet been standardized qualitatively or quantitatively, and widely accepted guidelines for the use of MRD in clinical practice are rarely available.
In this Special Issue, a panel of internationally recognized experts will focus on the current and future role of MRD in cancer with respect to MRD assessment techniques, MRD as a prognostic/predictive factor or therapeutic target, as well as MRD-based directions in the anticancer drugs development.
Potential topics include, but are not limited to:
- Systematic reviews on the current role of MRD in particular types of cancer;
- Novel methods of MRD assessment and MRD standardization efforts in cancer;
- The design and results of clinical trials testing MRD-driven treatment strategies;
- Original studies reporting the treatment of disease at MRD or subclonal levels in clinical practice;
- The significance of the genomic and spatial heterogeneity of MRD;
- The role of the tumor microenvironment regarding MRD persistence/eradication;
- MRD as a surrogate endpoint for new anticancer drug development and approval.
Prof. Dr. Krzysztof Jamroziak
Dr. Bartosz Pula
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- MRD
- measurable residual disease
- minimal residual disease
- cancer
- tumor microenvironment
- next generation sequencing
- flow cytometry
- imaging techniques
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
